Overview
WVE market data
Price History
WVE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.21 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.32 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.02 – $21.73 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.1K · P/B 5.91 · P/S 15.68.
Company News
Citigroup Maintains Buy on WAVE Life Sciences, Lowers Price Target to $19Benzinga · Jul 31, 2026, 8:43 PM
B. Riley Securities Maintains Buy on WAVE Life Sciences, Lowers Price Target to $22Benzinga · Jul 31, 2026, 3:42 PM
Wedbush Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $12Benzinga · Jul 31, 2026, 1:02 PM
8-K filing — Wave Life Sciences Ltd. (WVE)SEC EDGAR · Jul 30, 2026, 11:38 AM
WAVE Life Sciences Q2 EPS $(0.34) Misses $(0.31) Estimate, Sales $2.272M Miss $7.050M EstimateBenzinga · Jul 30, 2026, 11:30 AM
Wave Life Sciences Initiates Phase 2a Multidose Portion Of INLIGHT Trial, Placebo-Controlled Study Evaluating WVE-007 As Monotherapy In Individuals Living With Obesity With High BMI And ComorbiditiesBenzinga · Jun 24, 2026, 12:40 PM
Wells Fargo Maintains Overweight on WAVE Life Sciences, Raises Price Target to $14Benzinga · May 20, 2026, 1:35 PM
HC Wainwright & Co. Maintains Buy on WAVE Life Sciences, Lowers Price Target to $13Benzinga · May 19, 2026, 11:45 AM
Wave Life Sciences Announces Updated Data From Ongoing RestorAATion-2 Trial Of WVE-006, Investigational, GalNAc-Conjugated, Subcutaneously Delivered RNA Editing Oligonucleotide For Alpha-1 Antitrypsin DeficiencyBenzinga · May 18, 2026, 8:35 PM
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsightGlobenewswire Inc · May 14, 2026, 5:15 PM